canertinib dihydrochloride has been researched along with ruboxistaurin in 1 studies
| Studies (canertinib dihydrochloride) | Trials (canertinib dihydrochloride) | Recent Studies (post-2010) (canertinib dihydrochloride) | Studies (ruboxistaurin) | Trials (ruboxistaurin) | Recent Studies (post-2010) (ruboxistaurin) |
|---|---|---|---|---|---|
| 31 | 13 | 6 | 203 | 29 | 56 |
| Protein | Taxonomy | canertinib dihydrochloride (IC50) | ruboxistaurin (IC50) |
|---|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | 0.6484 | |
| Protein kinase C gamma type | Homo sapiens (human) | 0.3 | |
| Protein kinase C alpha type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C beta type | Homo sapiens (human) | 0.0054 | |
| Protein kinase C delta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C epsilon type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C zeta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | 0.2 | |
| Protein kinase C alpha type | Homo sapiens (human) | 0.36 | |
| Protein kinase C eta type | Homo sapiens (human) | 0.052 | |
| Protein kinase C gamma type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C beta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C epsilon type | Homo sapiens (human) | 0.6 | |
| Protein kinase C delta type | Homo sapiens (human) | 0.25 | |
| Protein kinase C eta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Homeodomain-interacting protein kinase 1 | Homo sapiens (human) | 0.1 | |
| Homeodomain-interacting protein kinase 4 | Homo sapiens (human) | 0.1 | |
| Homeodomain-interacting protein kinase 2 | Homo sapiens (human) | 0.1 | |
| Homeodomain-interacting protein kinase 3 | Homo sapiens (human) | 0.1 | |
| Protein kinase C theta type | Rattus norvegicus (Norway rat) | 0.32 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Russu, WA; Shallal, HM | 1 |
1 other study(ies) available for canertinib dihydrochloride and ruboxistaurin
| Article | Year |
|---|---|
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |